Follow Us:
Pemigatinib Exporter From India

Pemigatinib

Pemigatinib is an oral anticancer medication used for the treatment of adults with previously treated, unresectable or metastatic cholangiocarcinoma (bile duct cancer) containing specific FGFR2 gene fusions or rearrangements. It belongs to the fibroblast growth factor receptor (FGFR) inhibitor class of drugs. It works by selectively inhibiting FGFR1, FGFR2, and FGFR3, thereby blocking abnormal signalling pathways responsible for cancer cell growth and multiplication. This helps slow tumour progression. Pemigatinib is available in oral tablet form. Common side effects include high phosphate levels, hair loss, diarrhoea, fatigue, and changes in taste. Serious adverse effects may include retinal disorders and nail toxicity. Regular monitoring of phosphate levels and eye examinations is recommended during treatment.

  • Dosage Form:
  • Dosage Strength:
  • Manufacturer:
  • CAS No.:
  • Status:

Applications of Pemigatinib

Pemigatinib was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:

is okay

Contraindication of Pemigatinib

Availability of Pemigatinib

Delivery of Pemigatinib

Frequently Asked Questions

The most frequently asked questions focus on import, export, documentations, and regulation for Pemigatinib.

The is a pharmaceutical active pharmaceutical ingredient (API) used in manufacturing of Pemigatinib.

: Provides active pharmaceutical ingredients (APIs), customized production, and OEM/ODM services with research and technical cooperation across Europe, the USA, and India via Primeera Healthcare.

  • Therapeutic Goods Administration (TGA):
  • US Food and Drug Administration (USFDA):
  • European Medicines Agency (EMA):
  • African Medicines Agency (AMA):
  • National Medical Products Administration (NMPA):
  • Central Drugs Standard Control Organization (CDSCO):

Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Pemigatinib, subject to confirmation of its current regulatory status and eligibility for import into India.

Documentation Required for Pemigatinib Import

The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.

Import Regulations and dcoumentation for Pemigatinib

  • Import Documentation Assistance:
    Support with organising commercial invoices, packing lists, manufacturer details, product specifications, certificates of analysis, and other relevant documents required for regulatory review and customs processing.

  • Regulatory Coordination:
    Assistance with identifying applicable CDSCO requirements, import authorisations, and documentation procedures, subject to the product's regulatory status and the proposed import route.
  • Shipping and Customs Coordination:
    Coordination with relevant logistics providers and customs professionals to organise shipment documentation and facilitate clearance where legally permitted.
  • Compliance Verification:
    Preliminary review of available product and shipment documentation to identify potential regulatory gaps before procurement or dispatch. Import arrangements will proceed only after the applicable permissions and restrictions have been verified.

Customs Clearance and Compliance Handling of Pemigatinib Import

Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Pemigatinib, subject to confirmation of its current regulatory status and eligibility for import into India.

Export Regulations and dcoumentation for Pemigatinib

The export of Pemigatinib from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.

Documentation Required for Pemigatinib Emport

  • Export Documentation Assistance:
    Assistance with organising commercial invoices, packing lists, manufacturer details, Pemigatinib specifications, certificates of analysis, and other supporting documents required for Pemigatinib export and customs processing.
  • Regulatory Coordination:
    Support in identifying applicable country specific Pemigatinib export requirements, relevant manufacturing and export authorisations, and destination-country registration or import approval requirements, subject to the Pemigatinib regulatory status.
  • Shipping and Customs Coordination:
    Coordination with logistics providers, freight forwarders, and customs professionals to organise shipping documentation, export declarations, and customs clearance procedures where legally permitted.
  • Compliance Verification:
    Preliminary review of available Pemigatinib documentation, labelling, Pemigatinib manufacturing information, and destination-market requirements to identify potential regulatory gaps before dispatch. Export arrangements will proceed only after the applicable restrictions and authorisations have been verified.

Customs Clearance and Compliance Handling of Pemigatinib Export

Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Pemigatinib, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.

Product Export Support

If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.

Email Us

info@primeerahealthcare.com

Call Us

+(123) 456 789 00

Follow Us

Primeera Healthcare

Disclaimer

All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.